3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
21
Phase 2
11
Phase 1/2
5
Phase 1
4
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leiomyoma
1
Interventions
Magnetic Resonance Spectroscopy
3
Specimen Handling
2
Papillomavirus Vaccines
2
Lenalidomide
2
Immune Checkpoint Inhibitors
2
Imatinib Mesylate
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Diosmin
2
Dexamethasone
2
venetoclax
1
trametinib
1
tocilizumab
1
sofosbuvir-velpatasvir drug combination
1
semaglutide
1
ruxolitinib
1
rozanolixizumab
1
rasburicase
1
radium Ra 223 dichloride
1
pyrotinib
1
pirtobrutinib
1
oxycodone-acetaminophen
1
obinutuzumab
1
nirogacestat
1
nilotinib
1
ixazomib
1
idelalisib
1
human papillomavirus vaccine, L1 type 16, 18
1
fluciclovine F-18
1
darolutamide
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Letrozole
×
30 days
×
Clear all
NCT06143631
2026-05-20
PLUM
University of California, San Francisco
Phase 4
Recruiting
140 enrolled